Last reviewed · How we verify
IMA970A plus CV8102 and Cyclophosphamide
At a glance
| Generic name | IMA970A plus CV8102 and Cyclophosphamide |
|---|---|
| Also known as | Cyclophosphamide Injection 1 g |
| Sponsor | National Cancer Institute, Naples |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: